Innovative Med Concepts
Announces Receipt of FDA
Fast Track Designation for
IMC-1, a Novel Treatment
for Fibromyalgia

See Press Release.

IMC is leveraging cutting-edge scientific discoveries to target the underlying pathophysiology of fibromyalgia and related disorders.

See a video on the science

Fibromyalgia often presents with a pattern of comorbidities and overlapping symptomatology.

Watch a demonstration
image description

IMC is helping to improve patient outcomes by finally addressing an underlying cause of fibromyalgia and its related syndromes.

Learn more about IMC

Breakthrough Discoveries in Fibromyalgia

Innovative Med Concepts (IMC) is a biotech company with a pipeline of novel treatments for fibromyalgia and other related conditions that appear to share a common underlying pathophysiology—irritable bowel syndrome (IBS), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), chronic neck and back pain, and cognitive impairment. IMC's potentially game-changing, innovative treatments have emerged from breakthrough scientific discoveries in herpes simplex virus type 1 (HSV-1) reaction—the factor leading to many of the symptoms associated with fibromyalgia and its related conditions.

Promising New Throat Spray

NRP-1 is a proprietary throat spray designed to treat viral pharyngitis, a large unmet medical need and cause of most cases of pharyngitis. NRP-1 will also provide much needed relief for cancer patients undergoing head and neck radiation plagued with disabling oral mucositis/pharyngitis. This first-of-its-kind spray delivers the medication which then adheres to the posterior pharynx despite repeated swallows and saliva.